Healthy Volunteers
Conditions
Brief summary
The purpose of this study is to compare pharmacokinetics and safety of Irbesartan High and Amlodipine Fixed Dose Combination and coadministration of mono compounds in healthy adult volunteers
Interventions
Co-administration of Irbesartan High and Amlodipine
Irbesartan High/Amlodipine FDC
Co-administration of Irbesartan High and Amlodipine
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients who are 19 years or older on screening * Signed informed consent * Healthy Volunteer * Other inclusion applied
Exclusion criteria
* Clinically relevant/significant findings as evaluated by the investigator * Other exclusion applied
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUCt of Irbesartan High and Amlodipine | 72 hours |
| Cmax of Irbesartan High and Amlodipine | 72 hours |
Secondary
| Measure | Time frame |
|---|---|
| tmax of Irbesartan High and Amlodipine | 72 hours |
| half-life of Irbesartan High and Amlodipine | 72 hours |
| AUCinf of Irbesartan High and Amlodipine | 72 hours |
| Vz/F of Irbesartan High and Amlodipine | 72 hours |
| CL/F of Irbesartan High and Amlodipine | 72 hours |
| AUCt/AUCinf of Irbesartan High and Amlodipine | 72 hours |
Countries
South Korea